Fulvestrant (FaslodexTM) in advanced breast cancer: clinical experience from a Belgian cooperative study
peer reviewed ; Fulvestrant (FaslodexTM) is a new estrogen receptor (ER) antagonist with no agonist effects that is licensed for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer (ABC) who have progressed/recurred on prior antiestrogen therapy. The FaslodexTM Compassionate Use Program (CUP) provides expanded access to fulvestrant in countries where it is not yet available for patients who are not eligible to enter clinical trials. This analysis pools data from 402 patients who received fulvestrant as part of the CUP in Belgium, predominantly as 3rd- to 5th-lin... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2008 |
Verlag/Hrsg.: |
Kluwer Academic Publishers
|
Schlagwörter: | Advanced or metastatic breast cancer / Compassionate use / Endocrine / Fulvestrant / Postmenopausal / Human health sciences / Hematology / Sciences de la santé humaine / Hématologie |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26513793 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/229475 |